NCT05731440View on ClinicalTrials.gov

Fluselenamyl - Beta Amyloid PET Imaging for Alzheimer Disease

Active, not recruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

November 18, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Alzheimer Disease
Interventions
DRUG

18F-Fluselenamyl

Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer 18F-Fluselenamyl and will undergo an 18F-Fluselenamyl PET/CT scan.

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER